Pharmaceutical compositions containing anti-Fas antibody
AssigneeSankyo Company, Limited
InventorsNobufusa Serizawa, Kimihisa Ichikawa, Hiroko Yoshida
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition containing an anti-human Fas antibody having apoptosis inducing activity and a compound having a folate antagonist activity or a dihydrofolate reductase inhibiting activity, as active ingredients for the prophylaxis and/or treatment of an autoimmune disease or rheumatoid arthritis. According to the present invention, the amount of the anti-Fas antibody to be used can be reduced and thereby the possibility that a patient may become tolerant to anti-Fas antibody as a result of the production of antibodies against the anti-Fas antibody in the patient's body or the like can be decreased, and thus is provided a pharmaceutical composition which can be used for a long time.
Claims14
A pharmaceutical composition comprising effective amounts of pharmacologically active agents, wherein said pharmacologically active agents comprise:
- (a) an anti-human Fas antibody having an apoptosis inducing activity, said anti-human Fas antibody being monoclonal antibody HFE7A or a humanized antibody of monoclonal antibody HFE7A;
- and
- (b) a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity, said compound being methotrexate,
- the relative amounts of said pharmacologically active agents (a) and (b) being such that said pharmacologically active agents (a) and (b) exhibit a synergistic apoptosis inducing activity.
A pharmaceutical composition in the form of a solution comprising effective amounts of pharmacologically active agents together with a diluent therefor, wherein said pharmacologically active agents comprise:
- (a) an anti-human Fas antibody having apoptosis inducing activity which is monoclonal antibody HFE7A, or a humanized antibody thereof in a concentration of 0.1 to 100 ng/ml;
- and
- (b) methotrexate in a concentration of 0.05 to 5 nM, the relative amounts of said active ingredients (a) and (b) being such that they exhibit a synergistic apoptosis inducing activity.
A method for the treatment of a disease selected from the group consisting of rheumatoid arthritis, chronic thyroiditis, allergic encephalitis, myasthenia gravis, hyperthyroidism, extreme insulin resistance in diabetes, rheumatic fever, human hemolytic anemias, granulocytopenias, thrombocytepenias and systemic lupus erythematosis comprising administering to a human in need thereof effective amounts of the following active ingredients:
- (a) an anti-human Fas antibody having an apoptosis inducing activity, said anti-human Fas antibody being monoclonal antibody HFE7A or a humanized antibody of monoclonal antibody HFE7A;
- and
- (b) a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity, said compound being methotrexate,
- the relative amounts of the active ingredients (a) and (b) being administered such that said active ingredients (a) and (b) exhibit a synergistic apoptosis inducing activity.
A method for the treatment of a disease selected from the group consisting of rheumatoid arthritis, chronic thyroiditis, allergic encephalitis, myasthenia gravis, hyperthyroidism, extreme insulin resistance in diabetes, rheumatic fever, human hemolytic anemias, granulocytopenias, thrombocytepenias and systemic lupus erythematosis comprising administering to a human in need thereof effective amounts of a medicament in the form of a solution comprising pharmacologically active agents together with a diluent therefor, wherein said pharmacologically active agents comprise:
- (a) an anti-human Fas antibody having apoptosis inducing activity selected from the group consisting of monoclonal antibody HFE7A and a humanized antibody of monoclonal antibody HFE7A, in a concentration of 0.1 to 100 ng/ml;
- and
- (b) methotrexate at a concentration of 0.05 to 5 nM,
- the relative amounts of said pharmacologically active agents (a) and (b) being such that said pharmacologically active agents (a) and (b) exhibit a synergistic apoptosis inducing activity.
Dependencies are inferred from the claim text.